alexa
Reach Us +447480022765
Use of Inhaled Tobramycin for the Treatment of Severe Nosocomia Pneumonia | OMICS International | Abstract
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Use of Inhaled Tobramycin for the Treatment of Severe Nosocomia Pneumonia

Kuzovlev AN*, Moroz VV, Goloubev AM, Polovnikov SG, Stec VV and Varvarin VV

V.A Negovsky Scientific Research Institute of General Reanimatology RAMS, Moscow, Russia

*Corresponding Author:
Artem N Kuzovlev
V.A Negovsky Scientific Research Institute of General Reanimatology RAMS, build 2, 25 Petrovka str., Moscow 107031, Russia
Tel: 0079261887641
Email: [email protected]

Received date: August 20, 2012; Accepted date: September 25, 2012; Published date: September 27, 2012

Citation: Kuzovlev AN, Moroz VV, Goloubev AM, Polovnikov SG, Stec VV, et al. (2012) Use of Inhaled Tobramycin for the Treatment of Severe Nosocomial Pneumonia. J Pulmon Resp Med 2:130. doi: 10.4172/2161-105X.1000130

Copyright: © 2012 Kuzovlev AN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: The objective of the study was to estimate the efficacy and safety of Inhaled Tobramycin (IT) as an adjunct to systemic antibiotics in the treatment of severe Nosocomial Pneumonia (NP).

Patients and methods: 25 mechanically ventilated patients (out of 165 screened) were enrolled in the current observational single-center study. They were randomized to receive either IT (300mg, BID; group 1, n=15) as an adjunct to systemic antibiotics or for a correction of the regimen of systemic antibiotics (group 2, n=10). The primary outcome measure was resolution of NP and acute respiratory insufficiency. The CPIS, signs of Systemic Inflammatory Response Syndrome (SIRS) and oxygenation index were used as objective indicators of the clinical progress.

Results: The following signs of IT efficacy were detected in 87% of group 1 patients: a decrease of SIRS and CPIS scores within 2, 3 ± 1, 2 days of IT therapy (p<0,05); decrease of microbes titer to 103-104 CFU/ml (p<0,05); increase of microbes sensitivity to systemic antibiotics in 40% of patients; positive X-ray dynamics in 60% of patients within 9, 0 ± 2, 5 days of IT therapy. No serious side effects of IT were observed.

Conclusion: Administration of IT as an adjunct to systemic antibiotics is efficient and safe in 87% of patients with severe NP caused by multi resistant gram-negative bacteria.

Keywords

Recommended Conferences
Share This Page
Top